Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Investment in securities market are subject to market risks. Read all the related documents carefully before investing

End of Year Sale!
Grab Our Small Cap Recommendation
Service at a 60% Discount




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian stock markets slip further
Wed, 16 Jan 01:30 pm

Indian stock markets widened losses in the post noon trading session. Selling activity is being witnessed in most of the sectors, with those from banking, auto and IT spaces leading the pack of losers. Stocks from the oil and gas, healthcare and FMCG sectors are, however, trading in the green.

BSE-Sensex is down by 80 points and NSE-Nifty is trading down by 31 points. While BSE Mid Cap is trading down by 0.63%, BSE Small Cap index is trading up by 0.43%. The rupee is trading at 54.73 to the US dollar.

Most of the pharma stocks are trading mixed with Strides Arcolab and Dr Reddy's being among the top gainers and Aurobindo and Dishman Pharma among the losers. Ranbaxy and its parent company Daiichi Sankyo, announced that both the companies intend to integrate their business operations in Thailand. Ranbaxy and Daiichi Sankyo already have operations individually in Thailand. Both generate revenues of US$ 14 m each from this geography, which is less than 1% of their respective sales. In order to maximize and leverage synergies, both the companies intend to adopt a hybrid model and are expected to commence the business from April 2013. This integration will offer innovative and affordable, high quality generic medicines. The Thailand pharmaceutical market is the 2nd largest market in the ASEAN (Association of South East Asian Nations) countries. Ranbaxy was trading up by 0.86%.

Automobile stocks are trading mixed with Bajaj Auto being the biggest gainer and Tata Motors being the biggest loser. As per a leading financial daily, Hero MotoCorp is stepping up its rural promotional campaign in the wake of falling sales from increased competition faced from former collaboration partner Honda Motor Co. During the period April-December 2012, Honda reported a 37% spurt in two-wheeler sales as compared to a 2% decline registered by Hero MotoCorp. Reportedly, Hero MotoCorp derives more than 45% of its sales from non-urban regions. The company has been organizing free vehicle servicing and medical camps in over one lakh villages across the country to strengthen its presence and attract new customers. The company continues to remain optimistic about future rural demand based on factors such as rising rural income, better farm output and government's social spending programs. Hero MotoCorp is currently down 0.5%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian stock markets slip further". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.